| treatment |
|
comparator |
death (overall survival) | progression or death (progression free survival PFS) | objective response (ORR) |
|
|
| Pemetrexed | lung cancer (metastatic), in all type of patients | vs docetaxel | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | objective response (ORR) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Chen, 2008 | | | | | Hanna, 2004 | pemetrexed 500 mg/m(2) intravenously (i.v.) day 1 with vitamin B(12), folic acid, and dexamethasone | docetaxel 75 mg/m(2) i.v. day 1 with dexamethasone every 21 days | patients with advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy | | Li, 2012 | pemetrexed 500 mg/m(2) intravenously day 1 with vitamin B12, folic acid, and dexamethasone | docetaxel 75 mg/m(2) intravenously day 1 with dexamethasone | patients with histological or cytological diagnosis of stage IIIB or IV NSCLC, who were not suitable for curative therapy and had failed from prior first line chemotherapy regimen for at least 4 weeks | | Sun, 2013 | pemetrexed (500 mg/m(2); on Day 1 of each 21-day cycle | docetaxel (75 mg/m(2) on Day 1 of each 21-day cycle | second-line therapy for Chinese patients with locally advanced or metastatic non-small cell lung cancer |
|
| Pemetrexed | lung cancer (metastatic), in all type of patients | vs docetaxel plus carboplatin | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | objective response (ORR) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Jose, 2011 | carboplatin (area under the curve = 5 mg/ml × min) and pemetrexed (500 mg/m(2)) 21-day cycle (maximum of six cycles). | docetaxel (75 mg/m(2)). | first-line treatment for advanced, nonsquamous non-small cell lung cancer | | Socinski, 2010 | pemetrexed 500 mg/m and carboplatin area under the curve 6 once every 3 weeks for up to 6 cycles | docetaxel 75 mg/m and carboplatin area under the curve 6 once every 3 weeks for up to six cycles | Patients with stage IIIB (with pleural effusion) or IV non-small cell lung cancer and performance status 0 or 1 |
|
| Pemetrexed | lung cancer (metastatic), in all type of patients | vs pemetrexed | NS | by 33% | by 191% | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | 0.85 [0.62 1.17] | p=1.00 | 0 | -18 | 1 | Smit, | | progression or death (progression free survival PFS) | 0.67 [0.51 0.89] | p=0.04 | 0 | -18 | 1 | Smit, | | objective response (ORR) | 2.91 [1.18 7.15] | p=0.04 | 0 | -18 | 1 | Smit, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Smit, 2009 | Pemetrexed plus carboplatin | pemetrexed | |
|
| Vandetanib | lung cancer (metastatic), in all type of patients | vs pemetrexed | NS | NS | by 142% | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | 0.89 [0.73 1.09] | p=1.00 | 0 | -18 | 1 | De Boer, | | progression or death (progression free survival PFS) | 0.83 [0.68 1.01] | p=1.00 | 0 | -18 | 1 | De Boer, | | objective response (ORR) | 2.42 [1.42 4.12] | p=0.04 | 0 | -18 | 1 | De Boer, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| De Boer, 2011 | Vandetanib plus pemetrexed | pemetrexed | |
|
